Reply  by Kwon, Deborah H. et al.
A
H
C
T
T
I
t
m
a
t
r
h
i
p
h
e
a
i
s
fi
i
h
u
o
u
v
b
a
a
e
e
a
w
w
s
A
t
o
(
f
(
r
t
p
r
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 2 , N O . 1 , 2 0 0 9
© 2 0 0 9 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 0 9 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C .LETTERS TO THE EDITOR
*
B
*
G
N
I
E
R
1
2
3
4
5
6
R
W
(
i
o
c
D
a
s
e
p
s
l
t
m
b
a
n
A
m
c
t
o
mlcohol Septal Ablation for
ypertrophic Obstructive
ardiomyopathy
he Joys Are Brief: The Results Are Lasting
he recent article by Kwon et al. (1) in JACC: Cardiovascular
nterventions provokes mixed feelings. It is encouraging to note
hat 55 high-risk patients with hypertrophic obstructive cardio-
yopathy, who were surgical rejects underwent alcohol septal
blation (ASA) without any periprocedural mortality. However,
he rate of development of complete heart block (CHB)
equiring permanent pacemaker implantation was alarmingly
igh. If we exclude 11 patients who had permanent pacemaker
mplantation at baseline, then the rate of new permanent
acemaker implantation is actually 32% (14 of 44), which is
ighly unacceptable today. We believe that there are 2 possible
xplanations for this high rate of development of CHB. First,
ll the surgical rejects were subjected to alcohol septal ablation,
rrespective of the anatomy of the first septal unit (2). Alcohol
eptal ablation remains successful only when anatomy of the
rst septal unit is suitable. Performing ASA in all patients
rrespective of the anatomy of the first septal unit is bound to
ave higher complication rates. Second, the amount of alcohol
sed during the procedure clearly determines the complication
f CHB (3). There was no mention of the amount of alcohol
sed for ASA, so it may be an important explanation for the
ery high complication rate. Because these cases were done
etween 1997 and 2000, it is very possible that the amount of
lcohol used was not judicious. The relationship between
mount of alcohol used and development of CHB has been well
stablished only recently.
Further, this study was done at a center where surgical
xpertise and experience for myectomy is one of the best
vailable in the world and only surgical rejects were treated
ith ASA (4). This means very serious patients indeed under-
ent ASA. This is in contrast to the real-world setting wherein
urgical expertise and experience is not easily available. Only
SA rejects or poor anatomical candidates undergo myec-
omy. It is because of these differing practice patterns that
perators achieve differing levels of expertise in this procedure
5,6).
In today’s world, surgical expertise remains limited to a
ew centers, practicing patterns remain diagonally opposite
primarily ASA vs. primarily myectomy), and patient preference
emains inclined for a lesser invasive procedure. It is clear that
he joys of alcohol are brief; the results are lasting indeed! This
rocedure has been shown to be highly effective in surgical
ejects as well. oNeeraj Parakh, MD, DM
alram Bhargava, MD, DM, FRCP, FACC
Suite no-124, 1st floor, Academic block
.B. Pant Hospital
ew Delhi-110002
ndia
-mail: neerajparakh@yahoo.com
doi:10.1016/j.jcin.2008.10.007
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eply
e thank Drs. Parakh and Bhargava for their interest in our paper
1). Their letter highlights the long-standing controversy regard-
ng alcohol septal ablation (ASA) versus surgical myectomy for
ptimal management of patients with hypertrophic obstructive
ardiomyopathy (HOCM). We feel that the concerns raised by
rs. Parakh and Bhargava are a bit presumptuous. The mean
mount of alcohol injected, even by 1997 to 2000 standards for our
tudy population (1), was very low and the operators were
xtremely judicious in its use (mean volume: 2.65  0.81 cc). The
acemaker implantation rate is high, although our study shows
imilar incidence to studies from a comparable U.S. center (2). The
ikely reason for high pacemaker rate could be the possibility that
hese patients were relatively older, with more conduction abnor-
alities at baseline (12 of 55 patients had either left or right bundle
ranch block). Also, the assumption on the part of Drs. Parakh
nd Bhargava that we subjected all surgical “rejects” indiscrimi-
ately to ASA, irrespective of septal perforator anatomy, is wrong.
ll the alcohol injections were targeted to the contact point of the
itral valve to the septum, using echocardiographic (including
ontrast) guidance. The success rate of the procedure proves that
he procedure was performed appropriately (1).
As a high-volume practice, we do feel strongly that the choice
f procedural treatment of HOCM should be made after thorough
ultimodality imaging evaluation of the actual cause of dynamic
utflow tract obstruction. According to some estimates, up to 20%
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Letters to the Editor 75f patients have persistent symptoms due to left ventricular outflow
ract (LVOT) obstruction following ASA, which is likely due to
uboptimal procedural result (3–5). A recent study demonstrated
hat patients undergoing ASA usually end up with a basal
nferoseptal (as opposed to the preferred anteroseptal) infarction,
s compared with patients who undergo myectomy (6). That study
lso demonstrated that myectomy resulted in a “more complete”
elief of LVOT obstruction than did ASA (6). Another issue that
eeds attention, and perhaps should be studied in the future, is that
f myocardial scarring that is induced by ASA and the potential for
entricular tachyarrhythmias. Also, there are many other potential
easons for suboptimal results following ASA. A recent study (7)
ighlighted other important mitral subvalvular aspects leading to a
ailed ASA. It demonstrated the multifactorial etiology of dynamic
VOT obstruction, which includes mitral apparatus abnormalities,
uch as anterior displacement of the papillary muscles leaflet
longation and anteriorly displaced coaptation of the mitral valve
eaflets. We have also observed abnormal chordae attachment to
he base of the anterior mitral leaflet resulting in systolic “buckling”
f and dynamic LVOT obstruction, even in the setting of a
ormal-sized upper septum. In fact, 1 large surgical series identi-
ed abnormalities of the mitral valve in 19% of patients undergo-
ng surgical myectomy, which required further modification of
urgical technique to relieve obstruction (8). A priori identification
f such abnormalities might be crucial for an optimal result
ollowing ASA.
As aptly described in a recent editorial by Sigwart (9), “ASA was
ever devised to replace surgery for symptomatic patients with
OCM. It was intended to provide those patients, young and old,
ho have favorable (and accessible) anatomy, with an alternative to
pen heart surgery through the induction of a meaningful septal
ecrosis.” In conclusion, we stand by our assertion that at present,
ased on all the available data, surgical myectomy is the preferred
ption for young patients with drug refractory HOCM and for
hose with additional structural changes in the mitral valve,
apillary muscles, and coronary arteries. Furthermore, the most
mportant step in the management of patients with HOCM, even
efore they get to either the surgical suite or the catheterization
aboratory, is to identify the exact etiology of dynamic outflow tract
bstruction.
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irolimus-Eluting Stents or
ascular Brachytherapy for
n-Stent Restenosis After 3-Year
ollow-Up of the SISR
Sirolimus-Eluting Stent Versus
ascular Brachytherapy for
n-Stent Restenosis) Trial
Call for Caution?
e read with interest the article by Holmes et al. (1) in JACC:
ardiovascular Interventions. The main finding of the study was
hat in patients with bare-metal stent (BMS) restenosis, the use of
irolimus-eluting stents (SES) versus vascular brachytherapy
VBT) was associated with a significant reduction of target lesion
evascularization (TLR) without major differences in hard end
oints such as death or myocardial infarction (MI).
We would like to raise several issues and concerns that we have with
he methodology, the results, and the conclusions of this study.
First, due to slow enrollment in the vascular brachytherapy arm,
istoric control from the Gamma One (Localized Intracoronary
amma Radiation Therapy to Inhibit the Recurrence of Resteno-
is after Stenting) study, the first pivotal trial, was used to support
